Department of Chemistry, Queen's University, Kingston, ON K7L 3N6, Canada.
Mar Drugs. 2017 Aug 1;15(8):235. doi: 10.3390/md15080235.
The phylum proteobacteria contains a wide array of Gram-negative marine bacteria. With recent advances in genomic sequencing, genome analysis, and analytical chemistry techniques, a whole host of information is being revealed about the primary and secondary metabolism of marine proteobacteria. This has led to the discovery of a growing number of medically relevant natural products, including novel leads for the treatment of multidrug-resistant (MRSA) and cancer. Of equal interest, marine proteobacteria produce natural products whose structure and biosynthetic mechanisms differ from those of their terrestrial and actinobacterial counterparts. Notable features of secondary metabolites produced by marine proteobacteria include halogenation, sulfur-containing heterocycles, non-ribosomal peptides, and polyketides with unusual biosynthetic logic. As advances are made in the technology associated with functional genomics, such as computational sequence analysis, targeted DNA manipulation, and heterologous expression, it has become easier to probe the mechanisms for natural product biosynthesis. This review will focus on genomics driven approaches to understanding the biosynthetic mechanisms for natural products produced by marine proteobacteria.
门变形菌门包含了广泛的革兰氏阴性海洋细菌。随着基因组测序、基因组分析和分析化学技术的最新进展,人们对海洋变形菌的初级和次级代谢有了更全面的了解。这导致了越来越多具有医学相关性的天然产物的发现,包括用于治疗耐多药金黄色葡萄球菌 (MRSA) 和癌症的新型先导化合物。同样有趣的是,海洋变形菌产生的天然产物的结构和生物合成机制与陆地和放线菌的天然产物不同。海洋变形菌产生的次生代谢产物的显著特征包括卤化、含硫杂环、非核糖体肽和具有不寻常生物合成逻辑的聚酮化合物。随着与功能基因组学相关的技术(如计算序列分析、靶向 DNA 操作和异源表达)的进步,人们更容易探究天然产物生物合成的机制。这篇综述将重点介绍基于基因组学的方法,以了解海洋变形菌产生的天然产物的生物合成机制。